Search Results for "Dopamine agonists"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Dopamine agonists. Results 61 to 63 of 63 total matches.
Brexpiprazole (Rexulti) for Schizophrenia and Depression
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
of action Dopamine (D2) and serotonin (5-HT1A )
partial agonist; 5-HT2A antagonist
Formulation 0.25, 0.5 ...
The FDA has approved the oral, once-daily, second-generation
antipsychotic brexpiprazole (Rexulti –
Otsuka/Lundbeck) for treatment of schizophrenia
and as an adjunct to antidepressants for treatment
of major depressive disorder (MDD). Aripiprazole
(Abilify), a structurally similar second-generation
antipsychotic also comarketed by Otsuka (with BMS),
recently became available generically.
Drugs for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
(Chantix), a
nicotinic receptor partial agonist, is FDA-approved
as a smoking cessation aid.11 ...
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support.
Drugs for Alcohol Use Disorder
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021 (Issue 1639)
and inhibition of
dopamine release. In randomized, placebo-controlled
trials in adults with AUD ...
Consumption of alcohol has increased during the
COVID-19 pandemic. The Diagnostic and Statistical
Manual for Mental Disorders, 5th edition (DSM-5) defines
alcohol use disorder (AUD; previously called alcohol
dependence) as meeting ≥2 of the 11 criteria listed in
Table 1 in the past year. The lifetime prevalence of AUD
in the US population has been estimated to be about
30%. Despite this high prevalence and the associated
morbidity, mortality, and costs, only 3 drugs are FDA-approved
for treatment of the disorder.